RxDoctor Payments Data

Rourke Decker, DO

Family Medicine · Dickson City, PANPI 1053960088

Payments from drug & device makers

$10,334in general payments, 2019–2025

Across 454 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$580
  • Boehringer Ingelheim$556
  • Novartis$480
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$10,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,334 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$34,372
Medicare patients
171
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$54,309
MounjaroTirzepatide29$36,343
OzempicSemaglutide21$19,482
Diclofenac Sodium15$4,779
Albuterol Sulfate HfaAlbuterol Sulfate43$1,093
Fluticasone Propionate57$781
Gabapentin17$579
Atorvastatin Calcium75$564
Nifedipine ErNifedipine17$541
Duloxetine Hcl33$422
Rosuvastatin Calcium15$377
Amlodipine Besylate71$371
Lisinopril48$305
Metformin Hcl56$295
Losartan Potassium36$275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$556$54,30943 claims
Lilly USA, LLCMounjaro$580$36,34329 claims
Novo NordiskOzempic$1,025$19,48221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dickson City

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →